FinHER trial : Patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer

ABSTRACT: The FinHER trial is a multicentre phase 3 randomised adjuvant breast cancer trial that enrolled 1010 patients. The women were randomly assigned to receive three cycles of docetaxel or vinorelbine, followed by three cycles of fluorouracil, epirubicin, and cyclophosphamide.

ORGANISM(S): Homo sapiens

PROVIDER: GSE65095 | GEO | 2016/02/02

SECONDARY ACCESSION(S): PRJNA272973

REPOSITORIES: GEO